EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

β2-integrins as biomarkers in urothelial cancer

Marc Llort Asens iD, Imran Khan, Susanna Carola Fagerholm iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0326015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Marc Llort Asens und 2 weiteren Autor:innen. Beteiligte Einrichtung: MIBS research programme, Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Biomarkers, Tumor, CD18 Antigens, Urinary Bladder Neoplasms. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academy of Finland, Medicinska Understödsföreningen Liv och Hälsa, Magnus Ehrnroothin Säätiö.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

β2-integrins are a family of adhesion proteins expressed in immune cells that play multiple roles in anti-tumor immunity. β2-integrins regulate tumor infiltration of anti-tumorigenic immune cells such as cytotoxic CD8 + T cells and NK cells. However, they also regulate the activity of myeloid cells, such as macrophages, which can have both anti- and pro-tumorigenic properties. The role of β2-integrins in urothelial cancer remains poorly understood. Here, we have investigated the role of different β2-integrins, and their cytoplasmic regulators, in urothelial cancer, by utilizing RNA expression data. We found that ITGAL (encoding for CD11a) and FERMT3 (encoding for the integrin regulator kindlin-3) have a positive correlation with patient survival. EcoTyper analysis revealed increased infiltration of CD8 + T cells and NK cells in ITGAL high samples, but ITGAL or FERMT3 expression did not correlate with response to immunotherapy. In contrast, ITGAM and ITGAX (which encode for myeloid markers CD11b and CD11c) and FLNA (encoding for the integrin regulator filamin A) correlated with poor survival and reduced responsiveness to immunotherapy and critically regulate the tumor myeloid immune landscape (M1/M2 macrophages, cDC1 dendritic cells). Therefore, β2-integrins may be explored in the future as biomarkers to differentiate urothelial cancer patients with different immune landscapes, responding differently to therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorCD18 AntigensUrinary Bladder NeoplasmsHumansKiller Cells, NaturalCD8-Positive T-LymphocytesMaleFemaleGene Expression Regulation, NeoplasticUrothelium

Substanzen

Biomarkers, TumorCD18 Antigens

Autor:innen und Institutionen

  • MIBS research programme, Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland.

ORCID-Profile: Marc Llort Asens, Susanna Carola Fagerholm

Förderung

  • Academy of Finland
  • Medicinska Understödsföreningen Liv och Hälsa
  • Magnus Ehrnroothin Säätiö

Zitieren

APA

Llort Asens, M., Khan, I., & Fagerholm, S. C. (2025). β2-integrins as biomarkers in urothelial cancer. PLOS One. https://doi.org/10.1371/journal.pone.0326015

Vancouver

Llort Asens M, Khan I, Fagerholm SC. β2-integrins as biomarkers in urothelial cancer. PLOS One. 2025. doi:10.1371/journal.pone.0326015

BibTeX
@article{LlortAsens2025,
  author = {Llort Asens, Marc and Khan, Imran and Fagerholm, Susanna Carola},
  title = {β2-integrins as biomarkers in urothelial cancer},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0326015}
}
Kostenlos starten →